secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001193125-23-174497
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical reveals ~391K annual eligible procedures after expanded RECELL FDA approval
--------------------------------------------------------------------------------

- Expanded FDA indication for full-thickness skin defects opens ~391,000 annual eligible procedures.
- Traumatic wound market: ~127,000 procedures including degloving, crush, and avulsion.
- Surgical wounds (including cancer excision) total ~264,000 eligible procedures.
- Chronic wounds (DFU, VLU, pressure ulcers) account for ~128,000 annual procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523174497/0001193125-23-174497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523174497/d521007d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-174497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer